RecruitingEarly Phase 1NCT07715669

Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia

Role of Antidepressant Therapy to Improve Vascular Function After Preeclampsia


Sponsor

Anna Stanhewicz, PhD

Enrollment

40 participants

Start Date

Aug 30, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Preeclampsia is a condition in pregnancy where a woman develops high blood pressure and other complications. Women who develop preeclampsia are 4 times more likely to have heart disease later in life. They are also more likely to have depression after pregnancy. Why they are more likely to develop these conditions is not known. It may be because their blood vessels were damaged during pregnancy. Changes in blood vessel health can predict heart disease. These changes have been recorded after pregnancy in women who had preeclampsia. These changes have also been recorded in women who have depression. In the previous phase of this award, we found that women who had preeclampsia in pregnancy had changes in blood vessel health after pregnancy. We also found that if these women were taking a medicine to treat depression, their blood vessel health was normal. This could mean that treatment for depression can also increase blood vessel health in women who had preeclampsia. In this project we will study how changes in blood vessel health are related to preeclampsia and depression in women who have had both. We will also study how medicine to treat depression can improve blood vessel health after preeclampsia. We will do this by measuring how blood vessels work in women who have had preeclampsia compared to women who did not, and in women who have depression and women who do not. This will tell us more about why risk for depression and heart disease is higher in women who have had preeclampsia. It will also help us understand if medicine for depression can reduce cardiovascular disease risk after preeclampsia.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ascorbic acid (Vitamin C) and a drug called Paroxetine Hydrochloride for people with endothelial function and preeclampsia. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGParoxetine Hydrochloride

Localized delivery of paroxetine HCl to the cutaneous microvasculature via intradermal microdialysis.

DRUGAscorbic acid (Vitamin C)

Localized delivery of ascorbic acid to the cutaneous microvasculature via intradermal microdialysis.


Locations(1)

University of Iowa

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07715669


Related Trials